SOUTH SAN FRANCISCO, Calif., March 08, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter and year 2015 financial results on Tuesday, March 15, 2016 before the opening of the U.S. financial markets. Following the results announcement, management will host a conference call and live webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, March 15, 2016
- 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time
- Telephone 888-427-9376 (domestic) or 719-325-2420 (international); conference ID 3561455
- Webcast available at http://public.viavid.com/index.php?id=118445
- Telephone replay will be available beginning at approximately 11:30 a.m. Eastern Time on Tuesday, March 15, 2016 through 11:59 p.m. Eastern Time on Tuesday, March 29th by calling 877-870-5176 (domestic) or 858-384-5517 (international); conference ID 3561455.
- Webcast replay will be available on the Achaogen website at www.achaogen.com in the Investors section. A replay of the webcast will be archived for 30 days following the presentation.
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.